Brazil Withdraws Threat To Produce Generic AIDS Drug

Article

RIO DE JANEIRO-The Brazilian government has reached a tentative deal with Swiss pharmaceutical giant Roche to purchase the generic version of the AIDS drug Nelfinavir.

The South American country announced last week it would begin producing the drug in state-owned laboratories for sale January 1, 2002 because a deal had not been reached with the company. Brazil is one of the only countries in the world to guarantee treatment for all AIDS patients, including a free-of-charge program. Nelfinavir is part of the drug cocktail offered by the government for patients in need. They provided the drug to some 90,000 patients last year alone.

The Brazilian minister of health said the government was glad to have reached a deal with Roche, which will now sell the drug at a 40% reduced rate. The government will pay $35 million each year for the drug and ensure the company continued patent protection.

The Brazilian government had previously agreed to purchase other AIDS pharmaceuticals with New Jersey-based Merck after the company reduced rates of two medications by 70%.

The deal between the Brazilian government and Roche comes after 6 months of negotiations.

Brazil has the highest rate of AIDS infection in Latin America, with 210,5000 people infected.

Information from www.washingtonpost.com

Related Videos
Jill Holdsworth, MS, CIC, FAPIC, CRCST, NREMT, CHL
Jill Holdsworth, MS, CIC, FAPIC, CRCSR, NREMT, CHL, and Katie Belski, BSHCA, CRCST, CHL, CIS
Baby visiting a pediatric facility  (Adobe Stock 448959249 by Rawpixel.com)
Antimicrobial Resistance (Adobe Stock unknown)
Anne Meneghetti, MD, speaking with Infection Control Today
Patient Safety: Infection Control Today's Trending Topic for March
Infection Control Today® (ICT®) talks with John Kimsey, vice president of processing optimization and customer success for Steris.
Picture at AORN’s International Surgical Conference & Expo 2024
Infection Control Today and Contagion are collaborating for Rare Disease Month.
Related Content